MTOR and acute lymphoblastic leukemia: Dual NOTCH1 and mTOR targeting were also beneficial in preclinical models in which human T-ALL xenotransplanted mice treated with a combination of GSI and rapamycin showed increased survival compared to mice treated with GSI alone [107].